Specifically, ZIKV infection of human organoids upregulates the expression of innate immune receptor Toll-Like-Receptor 3 (TLR3), and compounds competitively inhibiting TLR3 can improve ZIKV pathologies [158]. This evidence concerns the gene TLR3 and Zika virus infectious disease.